Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report
The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleuk...
Gespeichert in:
| Veröffentlicht in: | Canadian respiratory journal Jg. 2019; H. 2019; S. 1 - 7 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Cairo, Egypt
Hindawi Publishing Corporation
2019
Hindawi John Wiley & Sons, Inc Wiley |
| Schlagworte: | |
| ISSN: | 1198-2241, 1916-7245, 1916-7245 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p=0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p=0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p=0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p=0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p=0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p=0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. |
|---|---|
| AbstractList | The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p=0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p=0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p=0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p=0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p=0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p=0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 10 /l to 0.14 ± 0.04 × 10 /l ( = 0.01) and FEV increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) ( = 0.04), while FeNO level has not changed (32.3 ± 8.4 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL ( = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL ( = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level ( = 0.81, = 0.008), as well as between changes in serum IL-25 and TSLP levels ( = 0.93, = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO[R], Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 [+ or -] 0.20 * [10.sup.9]/l to 0.14 [+ or -] 0.04 * [10.sup.9]/l (p = 0.01) and [FEV.sub.1] increased from 2.1 [+ or -] 0.5l (65.4 [+ or -] 8.8% of predicted) to 2.6 [+ or -] 0.4l (76.4 [+ or -] 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 [+ or -] 8.4 vs 42.9 [+ or -] 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 [+ or -] 17.2 pg/mL to 34.8 [+ or -] 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 [+ or -] 71.3 pg/mL to 275.6 [+ or -] 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 10 9 /l to 0.14 ± 0.04 × 10 9 /l ( p = 0.01 ) and FEV 1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) ( p = 0.04 ), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL ( p = 0.02 ) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL ( p = 0.02 ). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level ( r = 0.81, p = 0.008 ), as well as between changes in serum IL-25 and TSLP levels ( r = 0.93, p = 0.004 ) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359 . The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p = 0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359.The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p = 0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359. |
| Audience | Academic |
| Author | Januskevicius, Andrius Kalinauskaite-Zukauske, Virginija Malakauskas, Kestutis Miliauskas, Skaidrius Janulaityte, Ieva |
| AuthorAffiliation | 2 Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, Lithuania 1 Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, Lithuania |
| AuthorAffiliation_xml | – name: 2 Laboratory of Pulmonology, Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, Lithuania – name: 1 Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, LT-50161, Lithuania |
| Author_xml | – sequence: 1 fullname: Miliauskas, Skaidrius – sequence: 2 fullname: Janulaityte, Ieva – sequence: 3 fullname: Januskevicius, Andrius – sequence: 4 fullname: Kalinauskaite-Zukauske, Virginija – sequence: 5 fullname: Malakauskas, Kestutis |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31885750$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFk0tv1DAQgCNURB9w44wskBASpLUd58UBadUWqLQ8xJaz5SSTjYtjp7az1fIX-VN42S3tVkUoh8TON58nk5n9aEcbDVH0lOBDQtL0iGJSHhUZzrM0fxDtkZJkcU5ZuhOeSVnElDKyG-07d4ExI3nJHkW7CSmKNE_xXvRrBnbs0RQWoBwyLTodpO9ASaHiE7ByAQ06XnrzQ2pwSDh0pj1YBWPYiGmKhG7QebfsZY1m3ppeKDRd9kNnBiPBS41EG3gk0EzquQJ0YhysjvkEg1Hy59iLCgXqq_AStHfoKpyOZiEbC-iz0fFEKbDzYD81TmozdFKFxcT5rhdv0QTNOmM9-hZs1j-OHrZCOXiyuR9E39-fnh9_jKdfPpwdT6ZxnWXUx0VZM1bhSmAqaJOwFCc1y5Mmq0VVNbip0iqjBZR5ljVM1G0qGlY0OM-pKIqkLpOD6GztbYy44IOVvbBLboTkfzaMnXNhvawV8AYSjGkmRHAyAqQCEX4HbXBIIKcUguvd2jWMVQ9NHYpghdqSbr_RsuNzs-BZSVhJ0yB4tRFYczmC87yXrgalhAYzOk6ThLCEpiQL6Is76IUZrQ6lChTNC8poltxQcxE-QOrWhHPrlZRPMpJkpExKGqjn91D1IC_5bejwHihcDYSGCW3cyrC_ZX15K6ADoXznjBq9NNptg89ul-1vva4bOwB0DdTWOGeh5bX0YuUJKUjFCear6eGr6eGb6QlBb-4EXXv_gb9e453UjbiS_6M3KUNgoBU3NGFpQXDyGxyoMCQ |
| CitedBy_id | crossref_primary_10_1111_cea_14316 crossref_primary_10_1159_000507996 crossref_primary_10_1111_all_16092 crossref_primary_10_1111_cea_14231 crossref_primary_10_1111_resp_14506 crossref_primary_10_1111_all_16303 |
| Cites_doi | 10.1016/j.jaip.2013.11.013 10.1164/rccm.9120-11st 10.1056/nejmoa1403290 10.1016/j.cyto.2015.05.008 10.1016/j.cellimm.2010.04.008 10.1586/eci.10.58 10.1016/j.pharmthera.2016.06.009 10.1016/j.chest.2016.10.042 10.1164/rccm.201611-2234oc 10.1016/j.jaci.2011.01.066 10.1038/nm.3300 10.1016/j.jaci.2009.05.037 10.1016/j.rmed.2008.01.017 10.1172/jci124606 10.1016/j.jaci.2007.03.048 10.3389/fimmu.2015.00147 10.1038/nm.2735 10.1016/j.immuni.2019.03.018 10.2147/btt.s93954 10.1177/1753466618808490 10.2332/allergolint.11-rai-0376 10.1038/nri3786 10.1159/000447692 10.1586/1744666x.2016.1141049 10.1097/mcp.0000000000000443 10.7860/JCDR/2015/12235.5814 10.1016/j.cyto.2015.05.014 10.1111/j.1365-2222.2009.03241.x 10.1016/j.molmed.2005.02.002 10.5114/ada.2017.71428 10.1016/s2213-2600(17)30125-x 10.1111/j.1398-9995.1996.tb00042.x 10.1016/j.jaci.2010.07.019 10.1111/all.12275 10.1016/j.jaci.2011.08.031 10.1002/ppul.22708 10.1038/srep00023 10.1016/j.jaci.2015.12.1269 10.5578/tt.66695 10.1016/s0140-6736(12)60988-x 10.1016/j.jaci.2017.06.010 10.1159/000337752 10.1016/j.clinthera.2016.07.010 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. COPYRIGHT 2019 John Wiley & Sons, Inc. Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0 Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. 2019 |
| Copyright_xml | – notice: Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. – notice: COPYRIGHT 2019 John Wiley & Sons, Inc. – notice: Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0 – notice: Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. 2019 |
| DBID | ADJCN AHFXO RHU RHW RHX AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8FQ 8FV ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1155/2019/8607657 |
| DatabaseName | الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete Hindawi Publishing Complete Hindawi Publishing Subscription Journals Hindawi Publishing Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Canadian Business & Current Affairs Database ProQuest Canadian Business & Current Affairs Database (CBCA) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central CBCA Complete (Alumni Edition) ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection CBCA Complete ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: RHX name: Hindawi Publishing Open Access url: http://www.hindawi.com/journals/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: Publicly Available Content Database (Proquest) (PQ_SDU_P3) url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1916-7245 |
| Editor | Katsaounou, Paraskevi A. |
| Editor_xml | – sequence: 1 givenname: Paraskevi A. surname: Katsaounou fullname: Katsaounou, Paraskevi A. |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_de30026aa5b641e1bea2412d04b0722e PMC6914925 A613619392 31885750 10_1155_2019_8607657 1145810 |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: GlaxoSmithKline |
| GroupedDBID | --- 0R~ 19Q 24P 29B 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ 8FQ AAFWJ AAMMB ABUWG ACCMX ADBBV ADJCN AEFGJ AENEX AFKRA AFPKN AGXDD AHFXO AHMBA AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK DWQXO E3Z EBD EBS EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO ICQ IEA IHR IHW INH IPNFZ ITC J8S KQ8 M1P OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RIG RPM SV3 UKHRP 3V. AAJEY RHU RHW RHX AAYXX AFFHD ALUQN CITATION ALIPV NPM PMFND 7XB 8FK AZQEC K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c662t-89c44b0ba02a2d34503c473d6cabbd0db5b628e9766d4acf5ad48d0772a883c93 |
| IEDL.DBID | RHX |
| ISICitedReferencesCount | 15 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000503402500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1198-2241 1916-7245 |
| IngestDate | Fri Oct 03 12:51:46 EDT 2025 Tue Nov 04 01:50:37 EST 2025 Thu Sep 04 18:50:07 EDT 2025 Sat Nov 29 14:34:43 EST 2025 Tue Nov 11 10:56:04 EST 2025 Tue Jun 10 15:34:54 EDT 2025 Tue Nov 04 18:21:54 EST 2025 Thu May 22 21:27:32 EDT 2025 Mon Jul 21 06:06:44 EDT 2025 Sat Nov 29 04:09:10 EST 2025 Tue Nov 18 21:54:51 EST 2025 Sun Jun 02 19:16:24 EDT 2024 Thu Sep 25 15:10:16 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2019 |
| Language | English |
| License | This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 Copyright © 2019 Virginija Kalinauskaite-Zukauske et al. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c662t-89c44b0ba02a2d34503c473d6cabbd0db5b628e9766d4acf5ad48d0772a883c93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Guest Editor: Paraskevi A. Katsaounou |
| ORCID | 0000-0001-6870-343X |
| OpenAccessLink | https://dx.doi.org/10.1155/2019/8607657 |
| PMID | 31885750 |
| PQID | 2327824263 |
| PQPubID | 2032238 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_de30026aa5b641e1bea2412d04b0722e pubmedcentral_primary_oai_pubmedcentral_nih_gov_6914925 proquest_miscellaneous_2331432516 proquest_journals_2327824263 gale_infotracmisc_A613619392 gale_infotraccpiq_613619392 gale_infotracacademiconefile_A613619392 gale_healthsolutions_A613619392 pubmed_primary_31885750 crossref_citationtrail_10_1155_2019_8607657 crossref_primary_10_1155_2019_8607657 hindawi_primary_10_1155_2019_8607657 emarefa_primary_1145810 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-00-00 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – year: 2019 text: 2019-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Cairo, Egypt |
| PublicationPlace_xml | – name: Cairo, Egypt – name: Egypt – name: Oakville |
| PublicationTitle | Canadian respiratory journal |
| PublicationTitleAlternate | Can Respir J |
| PublicationYear | 2019 |
| Publisher | Hindawi Publishing Corporation Hindawi John Wiley & Sons, Inc Wiley |
| Publisher_xml | – name: Hindawi Publishing Corporation – name: Hindawi – name: John Wiley & Sons, Inc – name: Wiley |
| References | 22 44 23 24 25 26 27 28 29 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 40 41 20 42 21 (30) 2017; 169 43 |
| References_xml | – ident: 4 doi: 10.1016/j.jaip.2013.11.013 – ident: 21 doi: 10.1164/rccm.9120-11st – ident: 19 doi: 10.1056/nejmoa1403290 – ident: 43 doi: 10.1016/j.cyto.2015.05.008 – ident: 31 doi: 10.1016/j.cellimm.2010.04.008 – ident: 9 doi: 10.1586/eci.10.58 – ident: 15 doi: 10.1016/j.pharmthera.2016.06.009 – ident: 14 doi: 10.1016/j.chest.2016.10.042 – ident: 22 doi: 10.1164/rccm.201611-2234oc – ident: 40 doi: 10.1016/j.jaci.2011.01.066 – ident: 6 doi: 10.1038/nm.3300 – ident: 11 doi: 10.1016/j.jaci.2009.05.037 – ident: 12 doi: 10.1016/j.rmed.2008.01.017 – ident: 16 doi: 10.1172/jci124606 – ident: 10 doi: 10.1016/j.jaci.2007.03.048 – ident: 13 doi: 10.3389/fimmu.2015.00147 – ident: 27 doi: 10.1038/nm.2735 – ident: 18 doi: 10.1016/j.immuni.2019.03.018 – ident: 37 doi: 10.2147/btt.s93954 – ident: 2 doi: 10.1177/1753466618808490 – ident: 35 doi: 10.2332/allergolint.11-rai-0376 – ident: 5 doi: 10.1038/nri3786 – ident: 41 doi: 10.1159/000447692 – ident: 44 doi: 10.1586/1744666x.2016.1141049 – ident: 17 doi: 10.1097/mcp.0000000000000443 – ident: 26 doi: 10.7860/JCDR/2015/12235.5814 – ident: 42 doi: 10.1016/j.cyto.2015.05.014 – ident: 25 doi: 10.1111/j.1365-2222.2009.03241.x – ident: 8 doi: 10.1016/j.molmed.2005.02.002 – ident: 28 doi: 10.5114/ada.2017.71428 – ident: 20 doi: 10.1016/s2213-2600(17)30125-x – ident: 7 doi: 10.1111/j.1398-9995.1996.tb00042.x – ident: 1 doi: 10.1016/j.jaci.2010.07.019 – ident: 3 doi: 10.1111/all.12275 – volume: 169 start-page: 104 issue: 6 year: 2017 ident: 30 publication-title: Pharmacology & Therapeutics – ident: 29 doi: 10.1016/j.jaci.2011.08.031 – ident: 39 doi: 10.1002/ppul.22708 – ident: 36 doi: 10.1038/srep00023 – ident: 34 doi: 10.1016/j.jaci.2015.12.1269 – ident: 32 doi: 10.5578/tt.66695 – ident: 38 doi: 10.1016/s0140-6736(12)60988-x – ident: 23 doi: 10.1016/j.jaci.2017.06.010 – ident: 33 doi: 10.1159/000337752 – ident: 24 doi: 10.1016/j.clinthera.2016.07.010 |
| SSID | ssj0041794 |
| Score | 2.25354 |
| Snippet | The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref hindawi emarefa |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Allergies Asthma Care and treatment Cytokines Enzyme-linked immunosorbent assay Health sciences Inflammation Interleukins Monoclonal antibodies Omalizumab Pathogenesis Proteins Skin Statistical analysis |
| SummonAdditionalLinks | – databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hCiQuCMTLNMAgFXFAVv1-cAttKg6lqpQi9bbaVxSLxBtipyj8Rf4UM7ZjYgTqhWO8Y212Znbmm_XsDGNHeoY4wXjS1cajotqoxlT91I3ljI7dUrSPXtNsIr24yK6v88u9Vl-UE9aWB24Zd6xNSHGCELFMIt_40gh0OoH2IumlQWDI-iLq2QVTrQ2mtlrN92QMqV1yUruU9zjGaN_Pj7ME43dySXvOqKnZ31zMFfhb9Db63pyi4-_F3zDon6mUe77p7CF70IFKGLeLecTumPIx-4lmYLOEc8oKqsDOYLKi-xcLVDj3FPXuxmg42db2KyW-g6igORxcmA0-cIMYRKnhar5dFgqm9doucYLzLcrermxB96ShaS8OAqbo_RYGTm1laJrPhho__NgshQSkumwLt1ZAJ74wxX-zNnBhS3dMlxDR7sLEVkVpV3Syo2Bc1fOl-ABjmM4xMoA2QHjCvpxNrk4-uV3rBlclSVC7Wa4iFJAUXiACHUaxF6ooDXWihJTa0xKlGWQGsVCiI6FmsdBRpj2E-iLLQpWHT9lBaUvznIGUkZ-jzINU6miW0IdOFaRCYaSlEdz6Dnu_kyFXXV1zaq-x4E18E8ecJM47iTvsbU-9aut5_IPuI6lDT0NVuJsHqJu8001-m2467FmnTL_n8nE_-J7DXpNy8faya29l-BjRFYa0CFod9q6hIDuDy1Giuy6BTKGKXQPKwwGlWhXf-N7oaDCK1kMNXj7q1PsWdox2us87I1dxBOOIL6niv8Pe9MM0ASXulcZuiCZERI4gOkFmtFulnwjdCfWHRWakg000YPpwpCzmTQn0JPepquaL_yGlQ3afltqeq43YQb3emJfsrrqpi2r9qrErvwCePngv priority: 102 providerName: Directory of Open Access Journals – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9NAEF5BChIvHOIyDbBIRTwgq74PXlDapuKhRBEpUt-svUIsEm8aO0XhL_KnmLE3bow4HniMd6LdHc1-c-zODCEHcgp2gnK4LZWDRbVBjLH6qR3yKYbdYsBHp242EY9GycVFOjYBt9I8q9xiYg3UUguMkR-C5gdlhuXF3y8vbewahberpoXGTbKHlcqCHtk7Go7Gn7ZYjO216ntlcK1tVFbbp-9hCF6_mx4mEfjxqJp2lFJdu79O0GXwm7VYfXuGXvK3_He26K9PKnd01Om9_93dfXLXWKd00IjTA3JDFQ_JD8CT9YKe4fOikuopHS4xkWMOkmufgABfKUmPN5X-ii_oKStpHWWcqzV8sL2QskLS89lmkQs6qVZ6AROcbUCI9FLnmHBN6z7llNEJqNG5oie6VDjNR4UdJL6vF4xToBo3FWBLiqFjOoHVrBQd6cIeYDYjADgd6jIv9BJDRIIOymq2YO_ogE5m4GLQxtN4RD6fDs-PP9imB4Qtosir7CQVQcAdzhyPedIPQscXQezLSDDOpSN5yCMvUWBURTJgYhoyGSTSAZ-BJYkvUv8x6RW6UE8J5TxwUwZMjrkMphHemAovZgJcNglWsmuRt1shyIQpkI59OuZZ7SiFYYYikxmRscjrlnrZFAb5A90RylNLg-W86w969SUz6JBJ5aMzzBjsJnCVyxWs0_WkA1uPPU9Z5ImRxuu5XDhYrmORlyidWZM128JVNgAzDXxjsH4t8qamQMCC7Qhm8i6AKVj6q0O536EUy_wy2xntd0YBhkTnzwfmfPyDHf3tAcgMWpbZtfRb5FU7jBPgC8BC6TXS-GDagzUeATOas9ZOBHoJG80CM-LOKewwvTtS5LO6lnqUulie89nfl7VP7uAmmtBbn_Sq1Vo9J7fEVZWXqxcGdH4CskWHyA priority: 102 providerName: ProQuest |
| Title | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| URI | https://search.emarefa.net/detail/BIM-1145810 https://dx.doi.org/10.1155/2019/8607657 https://www.ncbi.nlm.nih.gov/pubmed/31885750 https://www.proquest.com/docview/2327824263 https://www.proquest.com/docview/2331432516 https://pubmed.ncbi.nlm.nih.gov/PMC6914925 https://doaj.org/article/de30026aa5b641e1bea2412d04b0722e |
| Volume | 2019 |
| WOSCitedRecordID | wos000503402500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: DOA dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Canadian Business & Current Affairs Database customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: 8FQ dateStart: 20130101 isFulltext: true titleUrlDefault: https://search.proquest.com/cbcacomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: 7X7 dateStart: 20130101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (ProQuest) customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: BENPR dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database (Proquest) (PQ_SDU_P3) customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: PIMPY dateStart: 20130101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Open Access customDbUrl: eissn: 1916-7245 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0041794 issn: 1198-2241 databaseCode: 24P dateStart: 19940101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF7RAhIXBOJlGsIgFXFAFn7b4Za2iYrURqEpUjhZ-4pikdghTorCX-RPMbN2Ql1AcLFk71j7mp35ZndnhrFDNUGcoB1hK-1QUG1kY4p-aodiQttuMcpHxySbiAeDZDzuDOsgSeXvR_io7dA8dzvvkggN7jDeY3tJSMx7cTreClzKoWUOj9F-tkkjbe-33_i3oXlMgH7jhcvxne8E8t0pmcLfsj8Bzpv3Jq8pov4Ddr9GkNCtpvwhu6XzR-wHrvn1HM7oClAJxQR6C3K2mCF32SfIZFdawfFmVXyhW-7ASzA7gTO9xg-2FwLPFVxON_NMwmi1LOZYwdkGJ7pYFBk5RYPJJQ4cRqjqZhpOilJTNeeasjx8X8-5AKQaVlFaS6DtXRhha5YaBkVud8njEIUs9Ioyy4sFbeNI6Jar6Zy_hy6MpmgGQGUNPGaf-r3L41O7ztNgyyjyVnbSkUEgHMEdj3vKD0LHl0Hsq0hyIZSjRCgiL9EIfCIVcDkJuQoS5SCu50niy47_hO3nRa6fMRAicDscYUMsVDCJ6FRTejGXaFYpRLKuxd5u5zCVdRBzyqUxS40xE4YpzXhaz7jFXu-oF1Xwjr_QHRE77Ggo5Lb5gGyY1is4Vdong5Vz7E3galdobKfrKQe7HnuettjTmpl-1eUi87uOxV4Sc6WVZ-tOpKRdhFJovyJCtdgbQ0FCBbsjee0bgYNC4bkalAcNSrnIvqbXSluNUhQVsvHzYc3e_xiO1pb301qilSkibwSTFN7fYq92xVQB3dLLdbEmGh_hNyLmCAejWiq7ilB3UDJYHIy4sYgag94sybOpiXcedVwKofn8_1p_wO7Ra7VN1mL7q-Vav2B35NUqK5dtthePY_NM8Jn0P7bZ7aPeYHjRNrsx-Db8cD783DYS5ifg_GzJ |
| linkProvider | Hindawi Publishing |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9NAEF5VBQQvHOIKLXSQWvGArNiOryAhFHqoVdOoKEXqm7tXiEXiTeOkVfhR_BH-FDM-0hpxPPWBx3gn2t3xzDcz650ZxjbVAP0EbQtLaZuKaqMYU_VTyxcDOnYLER_tvNlE2OtFp6ft4xX2vcqFoWuVFSbmQK2MpDPyJlp-NGZUXvzD5NyirlH0dbVqoVGIxaFeXGLIlr0_2MH3u-W6e7sn2_tW2VXAkkHgzqyoLT1P2ILbLndVy_PtlvTClgokF0LZSvgicCONZjpQHpcDnysvUjZ6oTyKWpKKLyHk3_JwPaRR0d6nCvmpmVf-FRsDeYtMY3XR3vebaGfbzSiww4AM4TUTmHcKyNOBOf7mS8twZ0gx-WXyO8_31wuc1yzi3oP_jZcP2f3S94ZOoSyP2IpOH7MfiJbzMXTp8lQGZgC7E0pTGaFeWjuonhdawfZiZr5SfgDwDPIz1JGe4wPL9YGnCk6Gi3EioT-bmjFO0F2gipiJSSidHPIu7MChj07CSMOOyTRNc6SpP8a3-ZgLQKrjor5tBnQwDn1czVRDz6RWh3I10TzBrsmS1EzoAExCJ5sNx_wddKA_xAAKijjqCft8I_x7ylZTk-rnDITwnDbHlxoK5Q0C-h4s3ZBLDEgVxgBOg72thC6WZfl36kIyivMw0PdjEtG4FNEG21pST4qyJ3-g-0jyu6ShYuX5AzP9EpfYFyvdolCfc9yN52hHaFyn4yobtx66rm6wZ6X0X83lIGw4doNtkDbERU7wEozjDjqhGPmjb99gb3IKgmPcjuRlVgkyhQqb1SjXapRykpzH10bXa6MIsrL2581SH__BjvVK4eLSFmTxlbY12OvlME1A9xtTbeZE08LABWONAJlR6PZyIrS61EYXmRHWtL7G9PpImgzzSvFB26Hioy_-vqwNdnf_5Kgbdw96h2vsHm2oOGRcZ6uz6Vy_ZLflxSzJpq9yuAN2dtOY8BMcHOQX |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9NAEF5V5RAvHOIKLXSRWvGArPhcO0gIhSYRVUtUlCL1zd0rxCLxpnHSKvw0_gJ_ihkfaYw4nvrAY7wTrXe8883O7ByE7KohnBO0LSylbSyqDdsYq59agRii2y0EfLTzZhNhvx-dnraON8j3KhcGwyorTMyBWhmJPvImaH5QZlhevDkswyKOO71303MLO0jhTWvVTqPYIod6eQnmW_b2oAPfes91e92T_Q9W2WHAkoy5cytqSd8XtuC2y13l-YHtST_0FJNcCGUrEQjmRhpUNlM-l8OAKz9SNpxIeRR5EgsxAfzfCD3G0PCLep8qLYCNvfIbbTDqLVSTVdB9EDRB57aaEbNDhkpxTR3mXQPy1GAOv_lKS9waoX1-mfzuFPxrMOeaduzd-5_5ep_cLc_ktF0I0QOyodOH5Aeg6GJCjzCoKqNmSLtTTF8Zg7xaHRDbC63o_nJuvmLeAOUZzX2rY72AB5YbUJ4qejJaThJJB_OZmcAER0sQHTM1CaaZ07w7O-V0AIeHsaYdk2mc5qPGvhnfFhMuKFAdF3VvM4oOczqAt5lp2jep1cYcTlBbtGuyJDVTdIxJ2s7mowl_Q9t0MALDihb21SPy-Vr495hspibVTwkVwndaHD5wKJQ_ZHhPLN2QSzBUFdgGToO8rjZgLMuy8NidZBzn5mEQxLhd43K7NsjeinpalEP5A9173MsrGixinj8wsy9xiYmx0h66ADiH1fiOdoSG93RcZcPSQ9fVDfKklISruRyAE8dukB2UjLjIFV6BdNyGwykDk6TlNsirnAJhGpYjeZltAkzBgmc1yq0apZwm5_Ha6HZtFMBX1v68W8rmP9ixXQlfXOqILL6SvAZ5uRrGCTDuMdVmgTQeGDRggzBgRiHnq4lAG2N7XWBGWEOAGtPrI2kyyivIs5aDRUmf_f21dshtgIL46KB_uEXu4HoK3-M22ZzPFvo5uSkv5kk2e5EjHyVn1w0JPwE7fezc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Levels+of+Epithelial-Derived+Cytokines+as+Interleukin-25+and+Thymic+Stromal+Lymphopoietin+after+a+Single+Dose+of+Mepolizumab+in+Patients+with+Severe+Non-Allergic+Eosinophilic+Asthma%3A+A+Short+Report&rft.jtitle=Canadian+respiratory+journal&rft.au=Kalinauskaite-Zukauske%2C+Virginija&rft.au=Januskevicius%2C+Andrius&rft.au=Janulaityte%2C+Ieva&rft.au=Miliauskas%2C+Skaidrius&rft.date=2019&rft.pub=Hindawi&rft.issn=1198-2241&rft.eissn=1916-7245&rft.volume=2019&rft_id=info:doi/10.1155%2F2019%2F8607657&rft_id=info%3Apmid%2F31885750&rft.externalDocID=PMC6914925 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1198-2241&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1198-2241&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1198-2241&client=summon |